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ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) is characterized by an abundant 
desmoplastic reaction driven by pancreatic stellate cells (PSCs) that contributes 
to tumor progression. Here we sought to characterize the interactions between 
pancreatic cancer cells (PCCs) and PSCs that affect the inflammatory and immune 
response in pancreatic tumors. Conditioned media from mono- and cocultures of 
PSCs and PCCs were assayed for expression of cytokines and growth factors. IP-10/
CXCL10 was the most highly induced chemokine in coculture of PSCs and PCCs. Its 
expression was induced in the PSCs by PCCs. IP-10 was elevated in human PDAC 
specimens, and positively correlated with high stroma content. Furthermore, gene 
expression of IP-10 and its receptor CXCR3 were significantly associated with the 
intratumoral presence of regulatory T cells (Tregs). In an independent cohort of 48 
patients with resectable pancreatic ductal adenocarcinoma, high IP-10 expression 
levels correlated with decreased median overall survival. Finally, IP-10 stimulated 
the ex vivo recruitment of CXCR3+ effector T cells as well as CXCR3+ Tregs derived 
from patients with PDAC. Our findings suggest that, in pancreatic cancer, CXCR3+ 
Tregs can be recruited by IP-10 expressed by PSCs in the tumor stroma, leading to 
immunosuppressive and tumor-promoting effects.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is 
the 10th most common cancer worldwide and ranks 
fourth in cancer-related mortality in the USA and fifth 
in the UK  [1, 2]. The high incidence of mortality is a 
consequence of late presentation, frequent inoperability 
of the cancer and poor response to the currently available 
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pharmacological modalities for PDAC. Nearly all patients 
diagnosed with PDAC die from the disease, with a 5-year 
survival rate of less than 5% [1]. The dismal outcome of 
current therapies underlines the need to better understand 
pancreatic cancer biology in order to identify novel 
approaches.
The histology of pancreatic cancer is notable 
for a prominent desmoplastic reaction predominantly 
driven by pancreatic stellate cells (PSCs). PSCs, called 
stellate cells because of their star-shape, can be activated 
by inflammatory stimuli, injury and cancer. When 
activated, PSCs lose their vitamin A storage droplets, 
express vimentin and α-smooth muscle actin and release 
high levels of extracellular matrix (ECM) proteins and 
growth factors that promote proliferation, survival and 
migration of PCCs [3]. Furthermore, this desmoplastic 
reaction acts as a physical obstacle to drug delivery and 
impairs the response to radiotherapy [4, 5]. PSCs were 
also shown to contribute to the immune suppressive 
environment of pancreatic adenocarcinoma [6]. In 
particular, it was reported that high levels of Galectin-1, 
secreted by the PSCs, induced apoptosis of CD4+ and 
CD8+ T cells [7]. Another recent study showed that 
PSCs secreted cytokines such as IL-6 that enhanced the 
differentiation of peripheral blood mononuclear cells 
(PBMCs) to myeloid-derived suppressor cells (MDSCs) 
and promoted their immunosuppressive activity [8]. 
Furthermore, activated PSCs were suggested to act as 
a physical barrier by blocking access of CD8+ T cells 
to cancer cells [9]. However, the mechanisms by which 
PSCs influence the immunoresponse are not completely 
understood and remain subject of active research 
[10, 11].
Because of the prominent desmoplastic reaction 
in pancreatic cancer, we designed a study to investigate 
biologically potent secreted chemokines specifically 
induced by coculture of hPSC with PCC. After 
comparing a panel of 50 factors produced by PSC alone 
or in coculture with PCC, IP-10 emerged as a cytokine 
induced by coculture that could have a significant effect 
on the immunological microenvironment of the tumors. 
Consistent with this hypothesis, IP-10 levels correlated 
with infiltration of regulatory T cells (Tregs) and survival 
in human PDAC.
RESULTS
Proinflammatory cytokines are released by PSCs
We characterized the expression of 50 cytokines, 
growth factors and chemokines in the conditioned media 
from PSCs and normal fibroblasts (MRC5) using a 
Multiplex Luminex suspension assay. Human PSC (hPSC) 
produced substantially higher levels of proinflammatory 
cytokines and chemokines than MRC5 (Table 1). Nine 
factors were expressed at least 4-fold higher in hPSC 
monoculture than in MRC5 monoculture (average 
concentrations displayed in Suppl. Table 1). These 
included interleukins: IL-6, IL-8, IL-1Rα, IL-15 and 
leukemia inhibitory factor (LIF); chemokines: melanoma 
growth stimulating activity (GRO)-α, Eotaxin, stromal 
cell-derived factor (SDF)-1α and interferon-γ inducible 
protein 10 (IP-10/CXCL10). Among these differentially 
expressed factors, only IL-6, IL-8 and SDF-1α were 
previously reported to be expressed by PSCs at the protein 
level [12, 13].
IP-10 is induced in coculture of PSCs with PCCs
To ask whether the presence of tumor cells changed 
the expression of cytokines and growth factors secreted 
by PSCs and vice versa, we examined differences in 
levels of the secreted factors between the conditioned 
media of PCCs and PSCs cocultures and monocultures 
using the same Luminex-based assay. Compared 
to the monocultures, coculture of Panc-1 cells with 
hPSC showed a 5-fold increase in IP-10 concentration 
(Figure 1A-B). Induction of IP-10 was confirmed by 
ELISA and was observed in cocultures with differing 
ratios of Panc-1/hPSC (Suppl. Figure 1). The level 
of IP-10 did not change significantly with increasing 
proportions of cancer cells.
In addition we examined expression of the 
same 50 factors from the conditioned media of PSCs 
cocultured with different pancreatic cancer cell lines 
(Suppl. Figure 2A-B). Coculture of PSCs with 5 of 
the 7 cell lines led to increased levels of IP-10. PSN-1 
cocultured with hPSC led to a 56-fold increase in IP-10 
levels compared to monocultures, coculture with Panc-1, 
MiaPaCa-2 and Hs766T showed around 4-fold induction, 
and coculture with Capan-1 showed nearly 2-fold 
induction (Suppl. Figure 2B). However, no difference 
in IP-10 expression was observed after coculture with 
Capan-2 or L3.6pl. We also noted that SCGF-β and 
HGF were decreased in the cocultures compared to 
the combined hPSC and PCCs monocultures (Suppl. 
Figure 2A, C-D). IP-10 expression was confirmed by 
ELISA with approximately 5-fold increase in IP-10 levels 
in coculture of hPSC with Panc-1, PSN-1, and MiaPaCa-2, 
2-fold with Capan-1, and 12-fold with Hs766T cells 
compared to the respective monocultures (Figure 1C). 
Overall, these results suggest that release of IP-10 is a 
common but not universal consequence of PCCs and PSCs 
cocultures.
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PCCs secrete soluble factors promoting IP-10 
expression by PSCs
We asked which cell type was responsible for 
IP-10 production and whether the induction could be 
triggered by soluble factors. To ask about the nature of 
the trigger for induction, PCCs and PSCs were plated in 
the same well, but separated by a 0.1-μm pore permeable 
membrane, thus allowing the passage of soluble factors 
but not cells between compartments. This indirect 
coculture of PSN-1 with hPSC resulted in increased 
IP-10 levels to a similar extent as direct coculture 
(Figure 2A). Quantitative PCR analysis performed 
on PSN-1 and hPSC cells 6 hr after indirect coculture 
Table 1: Factors secreted by PSCs and normal MRC5 fibroblasts. Supernatants were collected from 
hPSC and MRC5 monocultures and the levels of cytokines were measured using Multiplex suspension 
array. The relative expression of each factor was calculated by relating the average concentration in 
hPSC supernatants to that of MRC5 supernatant after culturing for 24 hr (n = 4). Factors highlighted in 
bold were significantly increased in supernatants from hPSC compared to those from MRC5. p, p-value; 
NA, ratio was not applicable (see Suppl. Table 1). t-test followed by Bonferroni’s post-test: *, p < 0.05; 
**, p < 0.001; ns, not significant.
Analyte hPSC vs. 
MRC5 
relative 
expression
p Analyte hPSC vs. 
MRC5 relative 
expression
p Analyte hPSC vs. 
MRC5 relative 
expression
p
Interleukins Chemokines/monokines Growth factors
IL-8 60.58 ** GROα 103.43 ** M-CSF 14.65 ns
IL-6 > 31.31 * Eotaxin 46.22 ** G-CSF 7.19 ns
LIF 8.28 ** SDF-1α 37.92 ** PDGF-BB 6.73 ns
IL-1Rα 6.25 ** IP-10 8.70 * GM-CSF 5.37 ns
IL-15 4.87 ** MCP-3 5.99 ns HGF 2.19
IL-2 4.68 ns RANTES 3.40 FGF basic 2.16
IL-17 4.17 ns MIP-1α 2.31 b-NGF 1.83
IL-4 3.88 MIF 1.74 SCF 1.51
IL-2Rα 2.91 MIG 1.60 VEGF 1.39
IL-16 2.22 CTACK 1.53 SCGF-b 1.03
IL-9 2.20 MCP-1 NA Apoptosis Mediator
IL-12(p40) 2.18 MIP-1β NA TRAIL 2.71
IL-1a 2.14 Inflammatory cytokines Adhesion molecules
IL-3 1.96 IFN-γ 6.91 ns ICAM-1 3.42
IL-7 1.83 TNF-α 4.63 ns VCAM-1 1.92
IL-18 1.71 TNF-β 1.71
IL-12(p70) 1.31 IFN-α2 1.61
IL-10 1.29
IL-13 1.11
IL-1β NA
IL-5 NA
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showed ~4-fold increased IP-10 mRNA in cocultured 
hPSC while no increase was observed in cocultured PSN-1 
cells (Figure 2B). In addition, siRNA knockdown of IP-
10 in hPSC abrogated the increase in IP-10 protein levels, 
while siRNA knockdown in PSN-1 did not affect IP-10 
levels in the cocultures (Figure 2C). These experiments 
demonstrate that PSCs are the major source of IP-10 in the 
cocultures and implicate soluble factors derived from the 
tumor cells in the induction. To extend this data, hPSC cells 
were cultured in conditioned media derived from PSN-1 
and Hs766T monocultures.  IP-10 secreted by hPSC cells 
increased by 3.8- and 3.5-fold, respectively after 48 hr 
(Figure 2D). Taken together, these data demonstrated that 
PCCs supply one or more soluble molecules that promote 
the expression and secretion of IP-10 by PSCs.
IP-10 is not sufficient to promote proliferation 
and migration of PCCs
CXCR3-binding ligands are known to stimulate 
proliferation and migration of tumor cells in glioma, 
colorectal carcinoma, prostate cancer, breast cancer and 
melanoma [14–19]. In order to investigate whether IP-10 
could evoke a response in PCCs, we examined the protein 
expression of its cognate receptor CXCR3 in PCCs and 
PSCs. We detected CXCR3 expression on the surface of 
Figure 1: IP-10 is upregulated when PSCs are cocultured with cancer cells. (A) Expression levels of factors in monocultures 
and cocultures of Panc-1 and hPSC. Data were quantified using the Multiplex suspension array and expressed as a ratio of coculture 
concentration divided by the sum from the monocultures for each factor (n = 4). §, not detected. ‡, above range of detection. (B) IP-10 
concentration (pg/mL) in the culture media of the conditions indicated measured in A. t-test: ***, p < 0.0001. (C) IP-10 levels in supernatants 
collected after 48 hr. Expression of IP-10 in the coculture was normalized to the sum of monocultures for each of the indicated cell lines 
(n = 4). Two-way ANOVA followed by Bonferroni’s post test: *, p < 0.05; ***, p < 0.0001.
Oncotarget11068www.impactjournals.com/oncotarget
all MiaPaCa-2 cells and on a subset of Panc-1, PSN-1 and 
hPSC cells (Suppl. Figure 3). In addition, we analyzed 
its expression by western blot. A band around 45 kDa, 
corresponding to the molecular weight of CXCR3-B 
isoform, was present in Panc-1, PSN-1, MiaPaCa-2, 
Capan-1, L3.6pl, Hs766T and hPSC cells (Figure 3A) [20]. 
A band of approximately 40 kDa, corresponding to the 
smaller CXCR3-A isoform, was detected as well in all the 
cells (PCCs and PSCs) and was particularly abundant in 
Capan-1 (Figure 3A).
Because CXCR3 is present in a large percentage 
of PCCs, we investigated the activation of IP-10/
Figure 2: Induction of IP-10 expression does not require cell contact in coculture. (A) IP-10 concentration in the supernatants 
from monocultures, direct and indirect cocultures was determined by ELISA. (B) IP-10 mRNA levels in monoculture and after coculture 
of PSN-1 and hPSC separated by a membrane (6 hr) assayed by qPCR. Values were normalized to GAPDH. (C) PSN-1 and hPSC were 
transfected with IP-10 siRNA and coculture conditions were set up as indicated 24 hr later. IP-10 expression in the coculture was evaluated 
with ELISA after 48 hr. NT, non targeting. (D) IP-10 concentration in the supernatant of hPSC with and without conditioned medium 
from PCCs determined by ELISA. The graph is representative of four independent experiments. Data are shown as mean ± SD. One-way 
ANOVA followed by Bonferroni‘s post-test: **, p < 0.001; ***, p < 0.0001. §, not detected. †, below limit of detection.
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CXCR3 signalling in PCCs. We analysed ERK and Akt 
phosphorylation, which are reported to be regulated 
by the activation of CXCR3 [21, 22]. Panc-1 and 
PSN-1 cells were stimulated with IP-10, but neither P-Akt 
nor P-ERK1/2 levels differed from unstimulated cells 
(Suppl. Figure 4A-B). Since the presence of serum could 
preclude IP-10 from activating CXCR3 signalling, cells 
were also serum-starved prior to stimulation. Capan-1, 
MiaPaCa-2, PSN-1 and Panc-1 cells were then exposed 
to IP-10 but levels of P-Akt and P-ERK1/2 showed no 
changes (Suppl. Figure 4C).
Despite not detecting a direct effect of IP-10 on 
CXCR3 signalling pathway, we decided to explore the 
possibility of a functional effect of IP-10 on pancreatic 
cancer cells. Therefore, we analyzed its chemotactic and 
proliferative effects on PCCs. In the chemotactic assay, 
IP-10 did not stimulate the migration of MiaPaCa-2 or 
PSN-1 cells (Figure 3B). Furthermore, IP-10 did not 
change proliferation of PCCs 96 h after stimulation, 
independent of seeding density and serum conditions 
(Figure 3C-D). Additionally, we tested the effects of 
IP-10 on migration and proliferation of PSCs. IP-10 
(100-1000 ng/mL) did not promote hPSC migration in 
vitro, and viability of hPSC remained unchanged over 
96 hr in the presence of IP-10 (data not shown). Taken 
together, these experiments showed that IP-10 had little 
or no direct effects on proliferation or migration of PCCs 
and PSCs in vitro but rather may have indirect functional 
effects in pancreatic cancer progression.
IP-10 and CXCR3 expression are elevated in 
human PDAC
We analyzed the expression of CXCR3 
by immunohistochemistry in pancreatic ductal 
adenocarcinoma samples of 30 patients. In addition, 
we compared the staining of CXCR3 and CD45 (pan-
leukocyte marker), CK8 (pancreatic epithelial marker) 
and α-smooth muscle actin (α-SMA, marker of activated 
fibroblasts/PSCs) between the tumor and the adjacent 
normal tissue for each patient (Figure 4A). We found 
CXCR3 positivity in 5–35% of tumor area in 17 out of 
30 patients, whilst 9 out of 30 patients had less than 5% 
CXCR3 positivity in tumor tissue and 4 patients showed 
Figure 3: Functional effects of IP-10 on PCCs. (A) Expression of CXCR3 in PCCs, PSCs and HEK293-EBNA/CXCR3-B analyzed 
by Western Blot. α-tubulin was used as loading control. (B) Microphotographs of PCCs migrated through the Boyden chamber in response 
to 0.5% FBS or IP-10 (24 hr). (C-D) Viability of PCCs after IP-10 addition determined using the MTT assay. Low/high refers to cell seeding 
density. Data are representative of two/three independent experiments. Data in the histograms are presented as mean ± SD.
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no CXCR3 expression (Figure 4C). In the corresponding 
normal tissue, 22 out of 30 samples had very little 
expression of CXCR3 (less than 5% of total area were 
positive for CXCR3), and only one sample showed 
CXCR3 expression in a wider area whilst 7 samples had no 
CXCR3 expression (Figure 4B). The expression patterns 
of CXCR3 in tumors were quite different; some tumors 
(55%) expressed CXCR3 in CK8+ epithelial cancer cells, 
some (33%) in the stroma, but most tumors (85%) showed 
a scattered expression pattern of CXCR3 throughout 
Figure 4: Expression of CXCR3 is elevated in PDAC compared to normal pancreas and is associated with leukocytes 
infiltration. (A) The panel shows representative staining for CXCR3, α-SMA, CD45 and CK8 for two patients (patient #1, patient #2). 
For each patient one area of the tumor (T) tissue is compared with one of the normal (N) tissue surrounding the tumor. (B-C) Pie charts 
represent the percentages of normal pancreatic tissue (B) and tumor tissue (C) that have none, more or less than 5% area stained positive 
for CXCR3. (D) The graph represents the percentage of tumors where colocalization is seen between CXCR3 and CD45, CK8 or α-SMA. 
Only tumors where CXCR3 is expressed in more than 5% of total area were analyzed.
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the tissue, which overlapped with the expression of the 
pan-leukocyte marker CD45 (Figure 4A, D). Altogether, 
these data demonstrate increased expression of CXCR3 in 
pancreatic cancer and that CXCR3 is primarily expressed 
by tumor-infiltrating leukocytes.
Furthermore, we determined IP-10 and CXCR3 
mRNA expression levels in 19 PDAC and 15 normal 
(adjacent to tumor tissues) pancreatic tissue samples by 
qPCR. Median mRNA expression of IP-10 and CXCR3 
was greater in PDAC patient samples than normal tissue 
by 3.8- and 77-fold on average respectively (Figure 5A). 
Moreover, levels of IP-10 correlated with CXCR3 
expression (Spearman’s rho: r = 0.625, p < 0.0001) 
suggesting an association between the presence of 
the ligand and its cognate receptor. Histopathological 
analysis of the tumors showed that PDAC containing 
high stromal desmoplasia expressed higher IP-10 mRNA 
levels (p = 0.029) and tended to have a higher expression 
of CXCR3 when compared to normal tissue (p = 0.063) 
(Figure 5B). Overall, we observed increased levels 
of mRNA expression for IP-10 and CXCR3 in PDAC 
compared to normal pancreatic tissue which is associated 
with increased amount of stroma present in the tumors.
High IP-10 expression levels correlate with 
decreased survival in PDAC patients
To explore the clinical relevance of IP-10, we 
examined the expression levels of IP-10 in an independent 
cohort of 48 patients diagnosed with PDAC, in which 
Figure 5: IP-10 and CXCR3 mRNA expression and correlation with leukocyte markers in PDAC. (A) mRNA levels of 
IP-10 and CXCR3 in PDAC tumors (T; n = 19) compared to the adjacent normal pancreatic tissue (N; n = 15). Line indicates the median 
with the interquartile range. (B) Amount (high/low) of stroma content in PDAC directly associates with the expression of IP-10 and 
CXCR3. IP-10 and CXCR3 levels were measured by qPCR, normalized to endogenous GAPDH control and fold changes calculated over 
the expression levels in pancreatic samples from normal control tissue. Mann Whitney test *, p < 0.05; **, p < 0.001; ***, p < 0.0001. 
(C) Kaplan-Meier analyses of patients with resected PDAC stratified by high and low expression levels of IP-10 (n = 48). HR, Hazard 
ratio; CI, confidence interval. (D) Spearman’s rho correlation between mRNA levels of the indicated genes, and IP-10 and CXCR3 levels 
in PDAC and normal pancreatic tissue. r, strength of the correlation; p, p-value; N, number of samples. Grey highlight indicates statistically 
significant correlation: *, p < 0.05; **, p < 0.001; ***, p < 0.0001; ns, not significant.
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mRNA microarray analysis of tumor tissues was performed 
and published by Dozynkiewicz and colleagues [23]. 
Clinical characteristics of patients are described in 
Supplementary Table 3. In this dataset, IP-10 expression 
was 2.18-fold greater in the PDAC specimens compared to 
normal tissue (p < 0.04, t-test). Moreover, using the median 
IP-10 mRNA expression value of the PDAC specimens as 
a cutoff, the cohort stratified into two groups with high 
expression levels of IP-10 in the tumor correlated with 
significantly shorter survival (p = 0.045, Log-rank test) 
(Figure 5C). The median overall survival of patients with 
low IP-10 expression was 30.1 months (95% CI 17.5–42.7) 
compared to 12.0 months (95% CI 3.2-16.8) for patients 
with high IP-10 levels. In order to elucidate the relation 
between IP-10 expression and stroma in human pancreatic 
cancer, IP-10 expression was normalized to the expression 
levels of α-SMA, a marker for activated fibroblasts and 
PSCs. Patients were then stratified again in two groups 
using the median IP-10/α-SMA value. The group with 
high IP-10/α-SMA ratio had significantly shorter overall 
survival (p = 0.015, Log-rank test) than those with low 
IP-10/α-SMA ratio (Suppl. Figure 5) indicating that 
IP-10 expression is not simply reflecting the percentage 
of stroma but it is an independent prognostic marker. The 
finding that IP-10 upregulation correlated with shorter 
survival provides evidence that IP-10 plays a functional 
role in pancreatic cancer. In addition, these data suggest 
that IP-10 levels may be used as a biomarker to predict 
survival in patients with resectable pancreatic ductal 
adenocarcinoma.
IP-10 and CXCR3 expression in PDAC 
correlates with the presence of Tregs
IP-10 is a known chemotactic factor for leukocytes, 
in particular, T cells. In order to test a potential association 
between IP-10 and leukocyte infiltration into tumors, 
we evaluated the mRNA expression levels of markers 
expressed by different leukocyte subpopulations in 
19 PDAC and 15 normal (adjacent to the tumor) 
pancreatic tissue samples by qPCR. These included CD3ε, 
CD4, CD8A, perforin 1 (pore forming protein 1, PRF1), 
neural cell adhesion molecule 1 (NCAM1, also called 
CD56), nitric oxide synthase 2 (NOS2 or iNOS), FOXP3, 
CTLA4, CD39 (also called ENTPD1), indoleamine 
2,3-dioxygenase 1 (IDO1) and IL-10.
CD3ε, CD8A, CD56 and NOS2 mRNA 
levels were similar in PDAC and normal tissue 
(Suppl. Figure 6A, C, I-J). However, median CD4 
levels increased by approximately 1.7-fold in PDAC 
compared to controls while PRF1 was decreased nearly 
2-fold (Suppl. Figure 6B, D). This suggests that there 
are more CD4+ T cells in the pancreatic tumor compared 
to normal tissue. The decrease in the levels of PRF1, a 
key effector molecule for cytolysis mediated by T and 
NK cells, in presence of CD8A and CD56 expression in 
PDAC suggests that the cytotoxic activity or the number 
of CD8+ T and NK cells may be reduced in the tumor. 
Median levels of FOXP3, CTLA4 and CD39, used 
here as surrogate markers for Tregs, were increased by 
approximately 16, 15 and 3-fold respectively, in PDAC 
tumors compared to normal tissue (Suppl. Figure 6E-G). 
Also, mRNA levels of IDO1 were increased by about 
13-fold in tumors compared to normal controls, while no 
significant changes were observed for IL-10 expression 
levels (Suppl. Figure 6H, K). Subsequently, we evaluated 
the association between expression of these markers and 
levels of IP-10 and CXCR3 in all samples. We found that 
IP-10 and CXCR3 levels correlated with the expression of 
CD3ε, CD4, FOXP3, CTLA4, CD39 and IDO1, molecules 
characteristically expressed by Tregs (Figure 5D). CXCR3 
expression also correlated with a decrease in PRF1 
levels (Figure 5D). Overall, the transcriptional analysis 
for leukocyte markers in PDAC samples indicates an 
association between IP-10 expression and its receptor 
CXCR3 with the presence of Treg and an immune-
suppressed PDAC microenvironment.
IP-10 stimulates chemotaxis of CD4+ and 
CD8+ T cells as well as Tregs isolated from the 
circulation of patients with PDAC
To test whether IP-10 induced chemotaxis of 
circulating leukocytes, we collected PBMCs from healthy 
volunteers (n = 6) and patients with PDAC (n = 6) and 
performed an ex vivo chemotactic assay. After incubation 
with and without IP-10, all migrated cells were collected 
and stained. The flow cytometry parameters and CXCR3 
staining used to distinguish the different leukocyte subsets 
are shown in Supplementary Figure 7A-B. Notably, we 
identified subsets of CD4+ T cells and CD8+ T cells 
expressing CXCR3 receptor on the cell surface and also 
subsets of Tregs (CD3+CD4+CD25+FoxP3+) and of CD3+ 
CD56+ cells expressing CXCR3 (Suppl. Figure 7B). As 
previously reported, the percentage of circulating Tregs 
was increased in PDAC patients compared to healthy 
volunteers (Figure 6C) [24]. In contrast, the percentage 
of circulating CD8+ T cells was lower in patients with 
PDAC while the overall percentage of CD4+ T cells and 
CD3+ CD56+ cells was similar between the two groups 
(Figure 6A-B, D).
In the presence of IP-10, PBMCs from PDAC 
patients showed a statistically significant increase in the 
numbers of migrating CXCR3+ leukocytes (Figure 6E, 
p < 0.05). IP-10 stimulated the recruitment of CXCR3+ 
CD4+ and CD8+ T cells as well as CXCR3+ Tregs in the 
PBMCs from PDAC patients but not from healthy controls 
(Figure 6E). Interestingly, the numbers of CD3+ CD56+ 
CXCR3+ cells were also augmented significantly by IP-10, 
but only in leukocytes from PDAC patients (Figure 6E). 
Taken together, these data demonstrate that IP-10 can 
act as a chemoattractant for CXCR3+ Tregs suggesting 
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Figure 6: IP-10 recruits CXCR3+ effector T cells as well as CXCR3+ Tregs. (A-D) Percentage of peripheral leukocytes that 
are CD4+ T cells (A), CD8+ T cells (B), CD3+ CD56+ cells (D) and the percentage of T cells that are Tregs (C) among healthy controls and 
patients with PDAC. Mann-Whitney U test: *, p < 0.05. (E) Relative ratio of migrating leukocytes in response to IP-10 over the number in 
the unstimulated controls. Two-way ANOVA followed by Bonferroni’s post test: *, p < 0.05; **, p < 0.001; ***, p < 0.0001. HC, Healthy 
control; P, patients with PDAC.
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that they share IP-10 chemotactic mechanisms with 
other effector T cells. The higher number of circulating 
CXCR3+ Tregs in PDAC patients may result from stromal 
induction of IP-10 and may also result in a higher number 
of infiltrating Tregs in the tumor. Furthermore, IP-10 was 
shown to recruit CD3+ CD56+ cells expressing CXCR3.
DISCUSSION
Since PSCs are the most prominent cell type in the 
extensive stromal reaction typical of PDAC, we asked 
whether we could identify specific factors involved in 
the interaction between PSCs and PCCs. As an initial 
approach, we compared the expression of a panel of 
cytokines and growth factors in the supernatant of 
PSCs compared to conventional fibroblasts in order to 
characterize the PSC-specific profile. Together with other 
factors already known to be secreted by PSCs such as IL-8, 
IL-6 and SDF-1α, we found that human PSCs secrete LIF, 
IL-1Rα, IL-15, GROα, eotaxin and IP-10. Subsequently, 
by comparing the expression of cytokines and growth 
factors from monoculture and coculture supernatants of 
PSCs and PCCs, we gained further insights into tumor-
stroma interactions establishing that PCCs regulate IP-10 
expression by PSCs.
IP-10 was significantly upregulated after coculture 
of PSCs with five of seven different PCCs. PSCs were the 
main source of IP-10 in the coculture as its transcription 
was upregulated specifically in PSCs but not in PCCs, 
and its secretion was abrogated following knock down of 
IP-10 in PSCs. IP-10, also called CXCL10, is a chemokine 
implicated in diverse processes such as inflammation and 
angiogenesis and it is expressed in patients with a wide 
range of diseases [25]. IP-10 is a known chemoattractant 
for activated T cells. The effects of IP-10 are mediated 
through binding to the CXCR3 receptor. The isoform 
A of CXCR3 is the receptor for two other IFN-γ inducible 
chemokines: MIG/CXCL9 and I-TAC/CXCL11 [26]. 
IP-10 together with platelet factor-4/CXCL4 also binds 
with high affinity to the isoform B of CXCR3 [20]. High 
levels of IP-10 and CXCR3 have been associated with 
chronic pancreatitis but a role for IP-10 in pancreatic 
cancer has not been previously reported [27].
Accumulating data implicate CXCR3 signaling 
in promotion of tumor growth, migration and invasion. 
For example, inhibition of CXCR3 signaling by either 
gene silencing or small molecule inhibitors decreased 
the number of pulmonary metastases formed by breast 
cancer cells [17, 28]. Activation of CXCR3 signaling 
was reported to promote tumor growth of glioma and 
basal cell carcinoma cell lines and to enhance invasion of 
melanoma and colorectal carcinoma cells [15, 18, 19, 29]. 
Using flow cytometry and western blotting analysis, we 
detected CXCR3 expression on the plasma membrane 
of PCCs and both CXCR3-A and –B isoforms were 
expressed at equivalent levels. However, PCCs did not 
migrate or proliferate in response to IP-10 stimulation in 
our experimental setting. Furthermore, IP-10 stimulation 
did not induce ERK or Akt activation in PCCs, suggesting 
that IP-10 may have little direct effects on PCCs. 
A possible explanation for these different biological 
outcomes between cancer cell types may rely on the 
fact that PCCs express equivalent levels of CXCR3-A 
and CXCR3-B isoforms. Indeed, activation of Ras was 
shown to downregulate CXCR3-B expression in breast 
cancer cell lines, which led to upregulation of IP-10 and 
increased proliferation, likely through activation of the 
remaining CXCR3-A isoform [16]. In prostate cancer cell 
lines, the ability of CXCR3-binding chemokines to induce 
migration was also dependent on aberrant expression 
of CXCR3-A and downregulation of CXCR3-B [14]. 
Since most PCCs express CXCR3-B at similar levels as 
CXCR3-A, this may counteract overall CXCR3 signaling. 
Another plausible explanation for our findings is that 
other chemokines that bind CXCR3, present in pancreatic 
cancer microenvironment, may mediate migration, 
invasion and growth of PCCs instead of IP-10. It may 
also be the case that in PCCs, CXCR3 is uncoupled 
from intracellular signalling and thus IP-10 does not 
modify the PCCs cellular response. Furthermore, a recent 
study reported the truncation of 2 amino acids at the 
N-terminal of IP-10 generated by the dipeptidyl peptidase 
IV (DPP4 or CD26) [30]. The resulting cleaved form of 
IP-10 is a dominant negative form of the protein, which is 
capable of binding CXCR3 but does not induce signalling 
[30]. We detected the expression of DPP4 in a number of 
PCCs (data not shown), hence this may be another possible 
explanation of why PCCs were not responsive to IP-10 
despite the expression of the cognate receptor.
IP-10 and CXCR3 mRNA levels were upregulated 
in pancreatic adenocarcinoma of patients obtained from 
pancreatectomy compared to normal pancreatic tissue, 
in two independent groups of patients. Furthermore, we 
found that IP-10 and CXCR3 levels in human PDAC 
correlated with higher tumor desmoplasia, suggesting that 
IP-10 expression may depend on the presence of PSCs in 
the tumor microenvironment similar to our in vitro model. 
Importantly, patients with surgically resected PDAC who 
displayed high intratumoral expression of IP-10 had 
shorter median overall survival by 18.1 months compared 
to patients with lower IP-10 levels.
These data raise questions about the potential 
mechanisms through which IP-10 may be affecting 
patient outcome. In our gene expression analysis of 
PDAC samples, we found that levels of both IP-10 and 
its receptor CXCR3 correlated with markers of Tregs 
(i.e. CD4, FOXP3, CTLA4 and CD39) within PDAC 
tissue but did not correlate with markers of CD8+ T cells. 
We also detected high expression of IDO1, a potent 
immunosuppressive molecule, in association with markers 
of Tregs and high levels of IP-10 and CXCR3 within 
PDAC. Tregs can suppress the activity of CD4+ Th1 and 
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effector cytotoxic T lymphocytes (CTLs) in the peripheral 
tissue where antigen is presented [31, 32]. Tregs can also 
induce dendritic cells (DCs) to produce IDO1 through the 
interaction of CTLA4 with CD80 and CD86 molecules 
expressed by DCs [33]. The correlation between IP-10 
and markers of Tregs, together with the local expression 
of IDO1 suggest the presence of an immunosuppressive 
environment within the PDAC tissues where IP-10 is 
upregulated. In addition, we found that CXCR3 expression 
levels were inversely correlated with PRF1, an effector 
molecule of CTLs and NK cells. Thus, it is likely that 
IP-10 and CXCR3 expression may be associated with 
the presence of functionally active Tregs, which in turn, 
may contribute to immunosuppression by blocking the 
cytotoxic activity of CTLs or NK.
Furthermore, we established that IP-10 is a 
chemoattractant for CXCR3+ CD4+ T cells and CD8+ 
T cells as well as CXCR3+ Tregs isolated from blood 
samples of PDAC patients and healthy volunteers. 
Interestingly, we also found that IP-10 was capable of 
recruiting a subset of T cells expressing CD3, CD56 
and CXCR3 exclusively in PBMC derived from PDAC 
patients. These cells are NKT-like cells whose role in 
tumors remains to be elucidated. Several studies have 
shown that IP-10 expression correlates with activity 
of activated T cells or other leukocyte subsets against 
different tumor types [34–37]. For example, in melanoma 
samples, IP-10 expression was associated with the number 
of CXCR3+ lymphocytes and correlated with spontaneous 
regression of melanoma lesions [34]. In colorectal cancer, 
high levels of IP-10 protein led to increased recruitment of 
effector CD8+ T cells and predicted longer recurrence-free 
survival [35]. IP-10 was found in 45% of human breast 
cancers and was associated with CXCR3 expression 
and lymphocytic infiltration [38]. Thus, the presence of 
IP-10 in solid tumors is often considered a good prognostic 
factor due to their ability to recruit activated lymphocytes. 
On the other hand, a recent study reported that Tregs 
expressing CXCR3 and the transcriptional factor typical of 
Th1 immunity T-bet accumulated in response to Th1-type 
inflammatory stimuli. This in turn blocked Th1 immune 
response in human ovarian cancer ex vivo [39, 40]. It was 
proposed that CXCR3+ Tregs may respond to CXCR3-
ligands to control strong Th1 and CTLs activation, in order 
to prevent an autoimmune response. This hypothesis is 
supported by the fact that in a mouse model of autoimmune 
hepatitis, adoptive transfer of CXCR3+ Tregs can induce 
tolerance and ameliorate the disease [41]. Likewise, other 
subsets of Tregs expressing Th lineage-specific molecules 
were shown to suppress the activity of the correspondent 
Th subset [42, 43]. In agreement with previous studies, 
we found that the presence of Tregs was increased in 
PDAC compared to normal pancreatic tissue [24, 44, 45]. 
Furthermore, the balance between the ratio of peripheral 
Tregs and total T cells is altered in pancreatic cancer 
patients [24]. Our data show that PDAC patients have 
on average double the number of Tregs in the peripheral 
blood compared to healthy controls. Thus, increased 
expression of IP-10 in pancreatic cancer tissue, although 
would lead to recruitment of CXCR3+ Tregs and CXCR3+ 
CD4+ and CD8+ T cells as shown in our in vitro assay, may 
preferentially contribute to increased infiltration of Tregs 
in the tumor due to the elevated numbers of circulating 
Tregs, hence inhibiting tumor immunoresponse.
It is important to consider that in other tumor types 
such as breast cancer and melanoma, IP-10 may drive 
an anti-tumoral response by recruiting CXCR3+ Th1 
lymphocytes [34, 35]. These opposing effects could be 
attributed to an altered balance between CXCR3+ Th1 and 
CXCR3+ Tregs. The imbalance between Tregs and CD8+ 
T cells in the circulation of pancreatic cancer patients could 
explain the results found in different cancer types. We have 
to consider also that CXCR3 is a promiscuous receptor 
and that, in addition to IP-10, it can bind CXCL11/I-TAC, 
CXCL9/Mig and CXCL4/PF-4 [46]. The presence of these 
chemokines in the tumour microenvironment could have 
additional effects on immune cell recruitment. Moreover, 
the way different chemokines affect the immune response 
may vary between tumor entities and even between 
patients and further experiments are needed to understand 
the role of this chemokine network in PDAC.
Based on our findings, we propose a model in which 
stromal expression of IP-10, induced by PCCs, recruits 
immunosuppressive CXCR3+ Tregs into PDAC. Tregs 
may then block the stimulation of T effector cells by 
antigen presenting cells, and/or directly inhibit T effector 
and NK cells, consequently favoring pancreatic tumor 
growth and progression. In conclusion, this study suggests 
that IP-10 upregulation in pancreatic cancer stroma may 
regulate recruitment of lymphocytes and consequently 
the immunoresponse against the tumor in a context-
dependent manner. Additionally, it indicates the potential 
use of IP-10 as a biomarker to predict survival in patients 
with resectable pancreatic adenocarcinoma. Validation 
of this model can provide novel insights regarding the 
physiological and pathological functions of IP-10, and can 
have important implication for the development of new 
multimodal therapeutic approaches.
MATERIALS AND METHODS
Cell culture
Human Panc-1, MiaPaCa-2, Capan-1, Capan-2, 
Hs766T and MRC5 were purchased from American Type 
Culture Collection, PSN-1 was obtained through an MTA 
with Merck & Co. and L3.6pl was kindly provided by Prof. 
I. Fidler (University of Texas, USA). These cell lines were 
grown in Dulbecco’s Modified Eagle’s Medium (DMEM; 
Sigma-Aldrich) with 10% FBS and penicillin/streptomycin 
(P/S). The human pancreatic stellate cells (hPSC) were 
obtained through a MTA with Prof. A. Masamune (Tohoku 
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University, Japan) and cultured in Ham’s F12/DMEM 1:1 
with 10% FBS and P/S. HEK293-EBNA/CXCR3-B cells 
were kindly provided by Prof. L. Lasagni (University 
of Florence, Italy) and cultured in DMEM 10% FBS, 
P/S supplemented with G418 and Hygromycin B from 
Invitrogen-Life Technologies. All cells were routinely 
tested for mycoplasma contamination using the 
MycoAlert® Assay kit (Lonza).
Multiplex cytokines analysis
Monocultures of 4×104 Panc-1, 4×105 hPSC and 
4×105 MRC5 cells and coculture of Panc-1 with hPSC 
(or MRC5) were established by plating the cells alone 
or together in 5 mL media. The conditioned media 
was collected 24 hr after culture and the concentration 
of 50 cytokines, growth factors and chemokines in 
conditioned media of PSCs and PCCs was assessed with 
the Human group I 27-Plex and the Human group II 
23-Plex cytokines arrays (Bio-Rad Laboratories). Data 
were acquired using a Luminex 100 plate reader and 
analyzed with the associated Bio-Plex® Manager 5.0 
software. The concentration of each factor in each sample 
was inferred from the exponential phase of the standard 
curve determined for each cytokine.
ELISA
The concentrations of IP-10 and GROα in culture 
supernatants were measured by ELISA using the human 
IP-10 and Duoset GROα ELISA Sets (#550926 BD 
Bioscience and #DY275 R&D Systems, respectively) 
according to manufacturer’s instructions.
RNA isolation
RNA isolation from adherent cells was performed 
using TRIzol (Life Technologies) according to 
manufacturer’s instructions, followed by DNAse treatment 
(Life Technologies).
Human tissue samples were obtained with approval 
of the local ethics committee and with informed, written 
consent from the patients. Thirty samples were obtained 
from patients with pancreatic carcinoma admitted to 
Surgical Department (Technische Universitaet Muenchen, 
Germany). These included 18 PDAC tissues (median 
age 68 years, range 42–83) and 12 normal peri-tumoral 
pancreatic tissues, of which 10 paired with PDAC 
samples. Median follow-up after surgery was 16.9 months. 
Histology-guided sample selection was performed by a 
pathologist to identify tumor and to exclude cancer cell 
contamination in the control samples. The classification 
of high and low stroma content was determined by 
P.K.J. Additionally, three normal peri-tumoral pancreatic 
tissues and one PDAC tissue were collected from patients 
admitted to the Churchill Hospital (Oxford University 
Hospitals NHS Trust, UK). Tissues were homogenized and 
RNA was isolated using the RNeasy Kit (Qiagen).
qPCR
cDNA preparation was performed according to 
standard procedures, using the RT-PCR ProtoScript 
M-Mulv kit (New England Biolabs). qPCR was performed 
using the TaqMan Gene Expression Master Mix (Life 
Technologies). Predesigned and pre-optimized TaqMan 
Gene Expression Assays (Life Technologies) used are 
listed in Suppl. Table 1. Relative measurement of the 
amplified product was performed using the comparative 
threshold cycles method by normalizing to endogenous 
GAPDH control and then calculating the fold-induction 
over the expression levels of a control sample (calibrator).
siRNA transfection
siGENOME non targeting pool #2 and human 
IP-10 ON-TARGETplus SMART pool were purchased 
from Dharmacon (Thermo Scientific) and siRNA 
transfections were performed following the manufacturer’s 
instructions. Briefly, cells were seeded in 6-well plate in 
complete media overnight followed by the addition of 
siRNA mixed with INTERFERin (Polyplus Transfection). 
The cells were further incubated 24 hr before being plated 
for coculture experiments.
Immunoblot analysis
Lysates were assayed by Western blot analysis 
for the expression of CXCR3 and α-tubulin using the 
antibodies #MAB160 (R&D Systems) and #14-4502 
(eBioscience), respectively. Akt antibody #9272, P-Akt 
(Ser 473) antibody #9271, ERK1/2 antibody #90101, 
P-ERK1/2 (phospho-p44/42) antibody #90102 were 
purchased from Cell Signaling. GAPDH antibody #G9545 
was obtained from Sigma-Aldrich.
Cell growth assay
Cell growth was assessed with CellTiter 
96 AQueous Non-Radioactive assay (Promega) accordingly 
to manufacturer’s recommendations. Cells were seeded 
in 96-well plates with or without IP-10 (10-600 ng/mL; 
PeproTech) in triplicates for each condition. After 4 days 
of culture, MTS solution was added and absorbance 
measured after 3 hr.
Peripheral blood mononuclear cells isolation
PBMCs were isolated from the blood of healthy 
donors and patients with PDAC using Lymphoprep™ 
density gradient medium in Sepmate™-50 tubes (StemCell 
Technologies). Isolated PBMCs were immediately frozen 
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in FBS with 10% DMSO until further use. Samples were 
obtained under the approval of the Oxford Radcliffe 
Biobank research tissue bank ethics and after informed, 
written consent of the patients.
Migration assays
Migration studies with PCCs were performed using 
cell culture inserts for 24-well plate with 8-μm pores (BD 
Biosciences). Cells were cultured overnight in 0.5% FBS 
medium then detached by gentle mechanical scraping. 
Cells were resuspended in serum free DMEM and placed 
in the inserts for 24 hr in the absence or presence of IP-
10 (0.25-600 ng/mL) in the bottom chamber. Experiments 
were done in triplicates. Cells that adhered to the membrane 
were fixed and stained with Hematoxylin and crystal violet.
Migration of PBMCs was performed using inserts 
for 24-well plate with 5-μm pores (Corning Life Sciences). 
Human PBMCs from patients with pancreatic cancer were 
thawed overnight in 2µl/mL Benzonase (Novagen) in 
RPMI with 10% heat inactivated FBS. PBMCs were not 
activated in order to preserve their biological cell activity 
as close as possible to the patients’ peripheral tissue. The 
following day, cells were starved for 20 min in RPMI 
with 0.1% FBS and 0.1% BSA. Afterwards, PBMCs were 
counted, resuspended in RPMI 0.1% FBS and 3 × 105 cells 
in 100 µL were added to the top of the Boyden Chamber. 
The bottom chamber contained 700 μL RPMI (1% FBS 
and 0.1% BSA) with or without rIP-10 (200 ng/mL). All 
conditions were done in triplicates. Transwells were then 
incubated for 3 hr and cells that had transmigrated into the 
lower chamber were collected, stained with antibody for 
flow cytometry analysis and resuspended in a solution of 
PBS/0.2% BSA containing an equal amount of Calibrite 
Beads (BD Bioscience), used for normalization. Leukocyte 
subpopulations were characterized by flow cytometry and 
the count of each leukocyte subtype was normalized to the 
number of Calibrite Beads in each sample.
Immunohistochemistry
Paraffin-embedded tissue microarray (TMA) of 
pancreatic cancer tissues versus corresponding normal 
tissues (AccuMax Array; Stretton Scientific) was 
deparaffinised, immersed in 10 mM citric buffer (pH 6.0) 
and microwaved for 10 min. The slide was washed and 
endogenous peroxidase activity was quenched by incubating 
the slide in 0.3% hydrogen peroxide for 20 min followed by 
successive blocking with TNB (Perkin Elmer) for 30 min. 
The slide was incubated overnight at 4°C with primary 
antibodies diluted in TNB. After 3 washes with PBS, the 
slide was incubated with biotinylated secondary antibody. 
Peroxidase staining (DAB substrate kit for peroxidase) was 
performed as recommended by the manufacturer (Vector 
Laboratories, Inc). The primary antibodies employed were 
against CXCR3 #C1366 (Sigma), α-SMA #M0851 (Dako), 
cytokeratin 8 (CK8) #AM142-5M (Biogenex) and CD45 
#ab8216 (Abcam). Staining was scored independently by 
SL and SYY to determine CXCR3 positivity and overlap of 
CXCR3 staining with α-SMA, CK8 and CD45.
Flow cytometry
Antibodies used to detect cell surface markers of 
PBMCs were: anti-human CD3-Alexa Fluor 700, anti-
human CD4-FITC, anti-human CD25-APC-eFluor 780, 
anti-human CD39-PE-Cy7 and anti-human CD56-PE from 
eBioscience; anti-human CD8-Pacific Blue, anti-human 
CXCR3 PE-Cy5 and PE-Cy5 mouse IgG1, κ isotype 
control from BD Bioscience.
Cells were resuspended in 5 µl Live/Dead solution 
(Invitrogen-Life Technologies) for 10 min at RT, then 
incubated with cell surface antibodies for 30 min at RT 
followed by intracellular staining for Foxp3 using the 
anti-mouse/rat/human FOXP3 (Biolegend) following the 
manufacturer’s instructions. Flow cytometry analysis 
was performed using a LSRII (BD Bioscience) and data 
analyzed with FlowJo software.
Transcript profiling
The accession number for expression microarray 
data in GEO is GSE55643.
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